Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124332 · ClinicalTrials.gov registry record · Phase 3
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
A Phase 3 study of Coronary Atherosclerosis, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
- 9
- Study locations
NCT00124332: Completed Phase 3 study of Coronary Atherosclerosis, sponsored by Sanofi.
NCT00124332 is a Phase 3 study of Coronary Atherosclerosis that has completed, run by Sanofi. The registered enrollment target is 839 participants, above the 191-participant average among 5 other Coronary Atherosclerosis trials with a reported enrollment target (339% higher). The trial reports 9 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00124332, a Phase 3 study of Coronary Atherosclerosis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as needed, in patients with abdominal obesity associated with current smoking and/or metabolic syndrome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimonabant (SR141716)
Study Locations (9)
Other
- sanofi-aventis, Australia - Macquarie Park
- sanofi-aventis, Belgium - Diegem
- Sanofi-Aventis Administrative Office - Laval
- sanofi-aventis, France - Paris
- sanofi-aventis Italy - Milan
- sanofi-aventis, Netherlands - Gouda
- sanofi-aventis Poland - Warsaw
- sanofi-aventis Spain - Barcelona
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
What the finished NCT00124332 record still lists
NCT00124332 is an interventional study that assigns participants to a tested intervention. The registered 839 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 5 other Coronary Atherosclerosis trials with a reported enrollment target (339% higher).
The record links to 1 condition, with Coronary Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00124332 lists 9 locations in 2 states (Other, Ohio).
Frequently Asked Questions
What is clinical trial NCT00124332 about?
NCT00124332 is a clinical study titled "STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)". The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as neede...
What is the current status of trial NCT00124332?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2005-01. Estimated completion is 2007-10.
What conditions does trial NCT00124332 study?
This clinical trial studies the following conditions: Coronary Atherosclerosis.
What interventions are being tested in trial NCT00124332?
The interventions under investigation include: Placebo (DRUG), Rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00124332?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00124332 being conducted?
This trial has 9 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
COMPLETED · Phase 3
-
Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
RECRUITING · NA
-
Using CTA Measures to Define Cardiac Risk In NFL Alumni
RECRUITING
-
Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)
COMPLETED · NA
-
Subclinical Atherosclerosis in HIV-infected Patients
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia